Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, VERTEX PHARMACEUTICALS INC / MA reported revenue of $12.00B, up 8.9% year over year. Operating margin was 34.8% and net margin 32.9%, on a free-cash-flow margin of 26.6% with capital expenditure at 3.6% of revenue. Every figure is computed directly from VRTX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $12.00B | 34.8% | 32.9% |
| FY2024 | $11.02B | -2.1% | -4.9% |
| FY2023 | $9.87B | 38.8% | 36.7% |
| FY2022 | $8.93B | 48.2% | 37.2% |
| FY2021 | $7.57B | 36.7% | 30.9% |
How does VRTX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.